Fero Industries, Inc. Changes Name to PharmaRoth Labs, Inc.
LAS VEGAS, March 25, 2013 /PRNewswire/ — PharmaRoth Labs, Inc. (OTCPink: FROI) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that the name of the company has been changed from Fero Industries, Inc. to PharmaRoth Labs, Inc. The company also relocated corporate headquarters to Las Vegas, Nevada from Canada.
Luis Lopez, CEO of PharmaRoth Labs states: “We changed the name to PharmaRoth Labs to better reflect our business. We are also in the process of changing our ticker symbol as well. In addition, we moved our official office to Nevada, as our CFO Barry Hall is located there. These changes exemplify our desire to move the company forward and be better positioned corporately. We will announce the ticker symbol change when we receive the notification. We have not changed the web address yet, but have purchased the URL of www.pharmaroth.com.”
Sucanon(®) is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “insulin sensitizers”. Pre-clinical and clinical studies show that Sucanon(®) and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin. Sucanon(®) has been approved for prescription sale in China and Peru. Sucanon(®) is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico.
For further information regarding Sucanon(®), please visit PharmaRoth Labs, Inc. website at www.feroindustries.com.
About PharmaRoth Labs, Inc.
PharmaRoth Labs, Inc. (OTCPink: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon(®), an oral treatment for Type-II diabetes. Sucanon(®) is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon(®) globally.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For investor relations contact:
Paramount Advisors, LLC
SOURCE PharmaRoth Labs, Inc.